Alliqua Inc. has entered into a licensing agreement with Celgene Cellular Therapeutics, a subsidiary of Celgene Corp., giving the two companies a greater market presence for their advanced wound-care technologies.
Under terms of the agreement, Alliqua received the right to develop and market the wound care products Biovance and Extracellular Matrix (ECM).
Biovance, which is scheduled to hit the market in the second quarter of 2014, is a collagen-based decellularized and dehydrated topical wound covering made from human amniotic membrane that was designed for the management of noninfected partial- and full-thickness wounds. ECM is a suite of wound management products made from extracellular matrix derived from the human placenta.
David Johnson, chief executive officer of Alliqua, said he welcomes the benefits this licensing agreement will bring to the wound care market. "Today, our investors can see a much clearer picture of our business focus, which remains firmly fixed on building a company in the wound care space that is capable of offering a superior suite of technological solutions for wound care practitioners and their patients. Biovance and ECM are complementary additions to our already well-received wound care portfolio that includes SilverSeal, Hydress and our other hydrogel-based products, as well as sorbion’s hydration response technology that was licensed earlier this year."